知镜 Cognispect · 医学文献与研究工作台

Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia.

Gong X, Liu Y, Fang Q, Gu R, Liu K, Lin D, Zhou C, Zhang G, Gong B, Wei S, Li Y, Li S, Wang Y, Qiu S, Liu B, Wang Y, Mi Y, Wei H, Wang J.
Blood · 2026-09-01 · PMID 42166560

文献摘要

Abstract The B-cell lymphoma 2 inhibitor venetoclax has shown promise in acute lymphoblastic leukemia (ALL), but its role in first-line therapy for newly diagnosed (ND) Philadelphia chromosome-negative (Ph-) ALL is undefined. In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years) with ND Ph- ALL received venetoclax combined with pediatric-inspired chemotherapy. The primary end point was the rate of measurable residual disease (MRD) negativity by multiparameter flow cytometry (MFC) after induction. The complete remission rate was 91.0%, and 73.0% of responders achieved MFC-MRD negativity, meeting the primary end point. After a median follow-up of 19.3 months, median overall and disease-free survival were not reached; estimated 2-year survival rates were 78.5% and 76.7%, respectively. Propensity score-matched analysis confirmed superior survival compared with historical chemotherapy-only controls. Grade ≥3 adverse events were primarily hematologic toxicities and infections, with an incidence comparable with that of the historical cohort. These results demonstrate that adding venetoclax to pediatric-inspired chemotherapy significantly improves MRD response and survival outcomes in newly diagnosed (ND) Ph- ALL, with a manageable safety profile. This trial was registered at www.clinicaltrials.gov as #NCT05660473.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。